Abstract:Based on literature data, the estimated global fatality rate for severely ill patients with septic shock is around 40%. [ 1–3 ] The current approach to treating septic Huk involves promptly administering fluids, using vasoactive medications, and prescribing antibiotics. Nevertheless, the extended utilization of vasoactive medications can result in a lengthened duration of hospitalization and heightened death rates. [ 3–6 ] The Exercise Guidelines for Surviving Sepsis suggest using HC adjuvant therapy for individuals with severe symptoms who need a norepinephrine dose of 0.25 mg/kg/min or higher for more than 4 hours. [ 6 ] The utilization of glucocorticoids in individuals experiencing septic shock may be traced back to the 1950s. The initial modest randomized controlled studies conducted by Hahn, Weitzman, and other researchers yielded contradictory outcomes. [ 7 , 8 ] In 1987, Bone et al showed that administering high dosages of glucocorticoids to patients with severe sepsis and septic shock could lead to an elevated rate of mortality during their hospital stay. [ 9 , 10 ] In 2002, Annane et al conducted a research which demonstrated that a 7-day regimen of low-dose hydrocortisone (HC) was effective in decreasing mortality rates. [ 11 ] In 2004, the Surviving Sepsis Campaign (SSC) guideline provided recommendations for the administration of glucocorticoids for patients diagnosed with septic shock. [ 12 ] In the studies of Sprung et al [ 13 ] and Annane et al, [ 11 ] 2 Sebille trials demonstrated that the use of hydrocortisone (HC) did not result in a decrease in the death rate of patients with septic shock. [ 11 , 13 ] As a result, the guidelines from the SSC were modified from a "recommended" status in 2004 to a continued "recommended" status in 2008. In 2011, Annane, D. conducted a study along with Renault, A. et al which shown that HC-assisted treatment of sepsis resulted in a reduction in 90-day mortality to 43% compared to 49%. [ 14 ] In 2010, Fang, F. also conducted a related study. A recent small-scale randomized controlled trial (COIITSS) conducted by et al demonstrated that the use of HC may lead to a decrease in 28-day mortality. [ 15 , 16 ] Consequently, the 2021 SSC guidelines have updated their recommendation about the use of HC in patients with septic shock, now considering it a weak recommendation. [ 2 ] A meta-analysis conducted in May 2023 examined the effects of low-dose hydrocortisone (HC) on persons with septic shock. The investigation found that HC may lead to an increased risk of mortality, with a relative risk (RR) of 0.86 for 90-day mortality. [ 17 ] Based on many research, our analysis determined that the use of low-dose hydrocortisone (HC) as an additional treatment may decrease the likelihood of death during a hospital stay for patients with septic shock. However, there is no specific information available regarding when to start HC therapy. We performed a meta-analysis by gathering data from published randomized controlled trials (RCTs) and cohort studies to evaluate the effects of starting low-doses of hydrocortisone (HC) at various time intervals on the clinical outcomes of patients with septic shock.

Effect of hydrocortisone-fludrocortisone combination on mortality in septic shock: a systematic review and meta-analysis

Effects and Safety of Separate Low-Dose Hydrocortisone Use in Patients with Septic Shock: A Meta-Analysis

Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation

[Therapeutic effect of hydrocortisone combined with vitamin C and vitamin B1 on patients with sepsis: a Meta-analysis]

Efficacy and safety of corticosteroids for septic shock in immunocompromised patients: A cohort study from MIMIC

Association of Corticosteroid Treatment with Outcomes in Adult Patients with Sepsis: A Systematic Review and Meta-analysis.

Early use of low-dose hydrocortisone can reduce in-hospital mortality in patients with septic shock: A systematic review and meta-analysis

[A Meta-Analysis to Evaluate the Effects of Corticosteroids on the Outcomes of Patients with Septic Shock].

Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock

Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial

Efficacy and Safety of Hydrocortisone, Ascorbic Acid, and Thiamine Combination Therapy for the Management of Sepsis and Septic Shock: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Can Corticosteroids Reduce the Mortality of Patients with Severe Sepsis? A Systematic Review and Meta-Analysis.

The Timing of Initiating Hydrocortisone and Long-term Mortality in Septic Shock

Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients with Sepsis: Meta-Analysis and GRADE Assessment

Effects of Hydrocortisone Combined with Vitamin C and Vitamin B1 Versus Hydrocortisone Alone on Microcirculation in Patients with Septic Shock: A Prospective, Double-Blind, Randomized, Controlled Trial

Comparison of Hydrocortisone with Combined Hydrocortisone, Ascorbic Acid, and Thiamine as an Adjuvant Therapy on Septic Shock Patients on Mortality: A Systematic Review and Meta-analysis

The Efficacy, Safety, and Optimal Regimen of Corticosteroids in Sepsis: A Bayesian Network Meta-Analysis.

Corticosteroid Administration is Associated with Improved Outcome of Patients Presenting High Inflammatory Cytokine Levels During Septic Shock

[Effects of different administration methods of hydrocortisone on blood glucose in patients with septic shock: a Meta-analysis].

[The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock].